Quantcast

Latest arGEN-X BV Stories

2011-07-26 05:00:00

ROTTERDAM, Netherlands, GHENT, Belgium, and PRINCETON, N.J., July 26, 2011 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology.

2009-12-03 02:00:00

ROTTERDAM, The Netherlands, December 3 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round.

2009-09-10 02:00:00

ROTTERDAM, The Netherlands, September 10 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful first closing of its Series A equity financing round.


Word of the Day
gubbings
  • The parings of haberdine; also, any kind of fragments.
The word 'gubbings' is a variant of the word 'gobbon', meaning 'a portion, gobbet.'